ImmunoCellular to File IND Application for Cancer Stem Cell Vaccine
Posted on: Thursday, 22 May 2008, 11:53 CDT
ImmunoCellular Therapeutics has announced that recently completed proof-of-principle studies demonstrate efficacy of its cancer stem cell vaccine technology in treating glioblastoma, a form of brain cancer, in preclinical animal models.
The company is planning to submit an investigational new drug (IND) application to the FDA later 2008 to commence a Phase I clinical trial for its cancer stem cell vaccine product, ICT-111, to treat glioblastoma. The company's cancer stem cell vaccine technology also could be applicable for multiple other cancers.
Manish Singh, president and CEO of IMUC, said: "We are excited about the data we have observed from the preclinical studies demonstrating a highly specific and potent immune response against cancer stem cells, as well as a survival advantage in the animals tested in preclinical studies."
Source: Datamonitor
Related Articles
- Scientists Develop Model That Could Help Identify Cancer Stem Cells
- ImmunoCellular Therapeutics Presents Data Demonstrating Immune Response Targeting Cancer Stem Cells
- IMUC Files Patent Application for Cancer Stem Cell Vaccine Technology
- ImmunoCellular Therapeutics Announces Filing of Patent Application for a Novel Cancer Stem Cell Vaccine Technology
- ImmunoCellular Licenses Cancer Stem Cell Technologies From Cedars-Sinai
- ImmunoCellular Therapeutics Announces Completion of Proof-of-Principle Studies Demonstrating Efficacy of Cancer Stem Cell Vaccine in Preclinical Model
- Arius's Therapeutic Antibody Inhibits Leukemic Cancer Stem Cells
- Cancerous Stem Cells Researched
- $20 Million Gift to Establish Cancer Stem Cell Research Center at Stanford
 |
 |
User Comments (0)
RSS Feeds